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Background: Postoperative adjuvant radiation therapy (ART) in T3 and R1 prostate cancer as well as salvage
radiation therapy (SRT) in case of postoperative biochemical failure (BF) are established treatments. Dose-intensified
postoperative radiation therapy (RT) schemes have shown superior biochemical control accompanied by increased
toxicity rates. In our study we evaluate a novel risk adapted dose-intensified postoperative RT scheme.
Methods: A consecutive series of prostate cancer patients receiving postoperative RT after radical prostatectomy
using helical Tomotherapy between 04/2012 and 04/2015 was analyzed retrospectively. RT was administered using
a simultaneous integrated boost (SIB) to the area at risk (37 fractions of 1.9 Gy, total dose: 70.3 Gy) being defined
based on histopathological findings (T3/R1 region) and in few cases according to additional diagnostic imaging.
The whole prostate bed was treated with a dose of 66.6 Gy (37 fractions of 1.8 Gy). Primary endpoints were acute
and late genitourinary (GU) and gastrointestinal (GI) toxicities. Secondary endpoints included patient reported
outcome as assessed by the International Prostate Symptom Score (IPSS), the International Consultation on
Incontinence questionnaire (ICIQ) and prostate cancer specific Quality of Life questionnaire QLQ-PR25, as well as
rates of BF.
Results: A total of 69 patients were analyzed. Sixteen patients underwent ART and 53 patients SRT, respectively.
The median follow-up was 20 months (range, 8–41 months). Seven (10.1%) and four (5.8%) patients experienced
acute grade 2 GU and GI toxicity. Two patients (2.9%) had late grade 2 GU toxicity, whereas no late grade 2 GI nor
any grade 3 acute or late GU or GI events were observed. When compared to the baseline IPSS scores (p = 1.0) and
ICIQ scores (p = 0.87) were not significantly different at the end of follow-up. Patient reported Quality of life (QoL)
showed also no significant difference. A total of seven patients (10.1%) experienced a biochemical recurrence with
the 2-year biochemical progression-free survival (bPFS) being 91%.
Conclusions: Postoperative RT for prostate cancer patients with a risk adapted dose-intensified SIB using helical
tomotherapy is feasible and associated with favorable acute and late GU and GI toxicity rates, no significant change
of IPSS-, ICIQ scores and patient reported QoL and results in promising bPFS rates.
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Prostate cancer is the most common male cancer in
developed countries and is the fifth most cause of death
from cancer worldwide [1]. Radical prostatectomy (RP)
offers good long-term control rates and survival in pa-
tients with cancer confined to the prostate [2]. However,
15 to 40% of patients develop biochemical failure (BF)
after RP within 5 years [3–5]. In patients with high risk
disease (extracapsular spread, seminal vesicle invasion or
positive surgical margins) adjuvant radiation therapy
(ART) improves biochemical progression-free survival
(bPFS), overall survival (OS) and distant metastasis-free
survival (DMFS) [6–9]. In the case of BF after RP,
salvage radiation therapy (SRT) is the only potential
curative treatment [10–12]. Moreover, dose-intensified
radiation therapy (RT) showed a further improvement of
biochemical relapse-free survival in the postoperative
radiation setting [13–15]. Recently published data con-
firmed the benefit of dose escalation in SRT. Tendulkar
et al. detected a significant reduction of BF after SRT
with an applied dose ≥66 Gy vs. < 66Gy when analyzing
a cohort of 2460 patients [16]. In addition, Stish et al.
evaluated data of 1106 patients with SRT and registered
a significantly reduced risk of BF when doses ≥68 Gy
were used [17]. On the other hand, postoperative RT is
also associated with genitourinary (GU) and gastrointes-
tinal toxicity (GI), especially in dose-intensified radiation
schemes. [13–15]. However, the increasing implementa-
tion of modern radiation techniques was reported to be
associated with a decrease in toxicity, even in dose in-
tensified radiation schemes [13, 18, 19]. Otherwise, the
first report of the prospective randomized SAKK 09/10
trial showed a significantly increased patient reported
genitourinary symptom burden in the dose intensified
SRT arm (70 Gy) compared to the patients in the 64 Gy
arm, irrespective of the applied radiation technique [20].
With the objective of combining the benefit of dose
escalated RT with an assumed lower GU and GI toxicity
rate using confined dose intensified radiation volumes,
we used the helical tomotherapy for postoperative
prostate cancer RT with a risk adapted dose-intensified
simultaneous integrated boost (SIB).
Methods
Between 04/2012 and 04/2015, 76 consecutive prostate
cancer patients who received postoperative RT after RP
were analyzed retrospectively. After exclusion of 7 patients
due to either macroscopic lymphnode metastasis accom-
panied by a prostate-specific antigen (PSA) > 4 ng/ml
(n = 5), bone metastasis (n = 1) or being lost to follow-up
(n = 1) the remaining 69 patients were analyzed. Patients
received ART [treatment 1–3 month after RP] (n = 16) or
SRT [treatment >3 month after RP or persistent PSA after
RP] (n = 53) using the tomotherapy treatment system.ART was performed in high risk patients with extracapsu-
lar spread, seminal vesicle invasion or positive surgical
margins (pT3, R1). SRT was administered in patients with
evidence of BF with two confirmed rises over a PSA value
of 0.2 ng/ml or in patients with persistent PSA after RP,
respectively. Furthermore, in some cases the SRT was
indicated in patients with two consecutive rises of PSA
with final PSA > 0.1 ng/ml or three consecutive rises
according to the definition of BF in the SAKK 09/10 trial
protocol [21]. Additional androgen deprivation therapy
(ADT) was administered based on risk factors according
to the discretion of the referring urologist.
Computed tomography (CT) based treatment planning
was performed in supine position with comfortably filled
bladder and empty rectum. Clinical target volume
(CTV) P comprised the prostate bed, CTV S comprised
the SIB-region and in the case of pelvic lymph node ra-
diation a CTV L contained this area. The planning target
volume (PTV) P (prostate bed) was defined as the CTV
P plus 5 mm in all directions. PTV S (SIB-region) was
defined as the CTV S plus 2 mm in all directions and
PTV L contained CTV L with a margin of 5 mm. The
posterior PTV P and PTV S margin differed from other
directions with a width of 3 mm. For delineation of the
SIB-volume the high risk region of the prostate bed was
defined considering the histological reports of prostatec-
tomy (R1 region, T3 region of infiltration or the tumor-
bearing area). Due to pN1 status and patients need for
security some patients also received radiation of pelvic
lymph nodes.
A prostate bed dose (PTV P) of 66.6 Gy (37 fractions
of 1.8 Gy, 7.4 weeks) and a SIB (PTV S) of 70.3 Gy (37
fraction of 1.9 Gy, 7.4 weeks) to the risk region of the
prostate bed was administered in helical tomotherapy
technique. A concurrent radiation of pelvic lymph nodes
(PTV L) was applied with a dose of 45 Gy in 11 patients,
50.4 Gy in 4 patients and 54 Gy in one case.
For the delineation European Organization for Re-
search and Treatment of Cancer (EORTC) guidelines
were considered. As additional information in 8 cases a
prostate specific membrane antigen gallium 68Ga labeled
positron emission tomography/computed tomography
(68Ga PSMA-PET/CT), in 2 cases a magnetic resonance
imaging (MRI) and in 2 cases a choline positron emission
tomography/computed tomography (choline PET/CT)
was used.
The GU and GI toxicities were classified using the
National Cancer Institute Common Terminology Criteria
version 4.0 (CTCAEv4.0). Acute toxicity events were de-
fined as symptoms during treatment and up to 3 months
after the end of RT. After >3 month the symptoms were
defined as late toxicities. Toxicity events were defined as
symptoms increasing in grade over the respective baseline
symptoms. Further monitoring of GU symptoms was
Table 1 Patient characteristics
Variable (N = 69)
n (%)





≤ 7 40 (58.0%)















Number of lymph nodes removed, median (range) 13.0 (1.0, 51.0)
Persistent PSA 4–12 weeks after prostatectomy
< 0.1 ng/mL 46 (66.7%)
≥ 0.1 ng/mL 15 (21.7%)
< 0.5 ng/ml 54 (78.3%)
≥ 0.5 ng/ml 7 (10.1%)
missing 8 (11.6%)
PSA at start of RT
< 0.5 ng/mL 57 (82.6%)
≥ 0.5 ng/mL 12 (17.4%)
Age at start of RT median (range) in years 66 (45, 78)
Time from surgery to RT start, median
(range) in months
10.0 (1.0, 155.0)











Abbreviations: PSA prostate specific antigen, RT radiation therapy, ECOG Eastern
Cooperative Oncology Group, ADT androgen deprivation therapy
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Score (IPSS) and the International Consultation on
Incontinence questionnaire (ICIQ). The Quality of Life
(QoL) was detected with the IPSS-QoL score and
EORTC Quality of Life Questionnaire prostate cancer
specific module PR25 (QLQ-PR25). The QLQ-PR25
module was used to measure symptom scales (urinary
symptoms, bowel symptoms) and functional scales (sexual
activity, sexual functioning). The GU and GI toxicities
were assessed in three time periods using CTCAEv4.0
classification: baseline (before start of radiation therapy),
acute (during and at end of RT) and late (>3 month after
RT). IPSS, ICIQ, IPSS-Qol and QLQ-PR25 were assessed
before beginning of RT and at the end of follow-up.
BF after completed RT was defined as any PSA exceed-
ing 0.4 ng/ml and rising. In case of BF further diagnostics
like 68Ga PSMA-PET/CT were applied to investigate the
localization of recurrence.
The primary objective was to determine the rates of acute
and late GU and GI toxicities. Secondary objectives were to
document patient related outcomes as assessed by the IPSS
and the ICIQ, measure patient reported QoL and to
describe the rate of bPFS. Differences in IPSS sums, ICIQ
sums and QLQ-PR25 scores between baseline and post-
treatment were compared performing the students t-test.
Actuarial bPFS rates were estimated using the Kaplan-
Meier method. Time to event was calculated from the
first day of treatment until biochemical recurrence or
the last follow-up visit. Influence factors for bPFS were
analyzed using the Cox-regression method. Two-sided
p values <0.05 were considered statistically significant.
The data were analyzed in SPSS (SPSS Inc., Chicago,
IL, version 24.0).
The internal institutional review board approved a
waiver for research authorization.
Results
Patient characteristics
The patient characteristics were summarized in Table 1
and the median follow-up was 20 month (range 8–
41 months). Before RP patients had a median PSA level of
10 ng/ml. RT was delivered after a median of 10 months
after RP (range, 1–155 months). PSA levels prior to RT
ranged from 0 to 2.05 ng/ml with a median of 0.21 ng/ml.
23 patients (33.3%) were treated with an ADT. In the last
follow up survey still 12 patients (17.4%) received an
ADT. The ADT was given according to the discretion of
the referring urologist. The 23 patients with ADT met one
or more of the following treatment criteria: Either a PSA
doubling time < 3 months, a symptomatic local disease, a
pN1 status or a high PSA value > 0.7 ng/ml before start of
RT. In 15 patients a concurrent radiation of pelvic lymph
nodes due to pN1 status and in one case by reason of
patients need for security was applied.
Table 2 Acute and late genitourinary and gastrointestinal toxicity
GU Toxicity CTCAE highest
gradea
During/End





Dysuria 0 60 (87.0%) 65 (94.2%)
1 6 (8.7%) 3 (4.3%)
2 3 (4.3%) 0 (0.0%)
Hematuria 0 69 (100.0%) 66 (95.7%)
1 0 (0.0%) 2 (2.9%)
Urinary
frequency
0 59 (85.5%) 59 (85.5%)
1 6 (8.7%) 8 (11.6%)
2 4 (5.8%) 1 (1.4%)
Urinary
incontinence
0 68 (98.6%) 57 (82.6%)
1 1 (1.4%) 10 (14.5%)
2 0 (0.0%) 1 (1.4%)
Urinary retention 0 67 (97.1%) 57 (82.6%)
1 2 (2.9%) 11 (15.9%)
Urinary urgency 0 57 (82.6%) 61 (88.4%)
1 12 (17.4%) 7 (10.1%)
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At the baseline (before onset of RT) 56 patients had
grade 1, 8 patients had grade 2 GU and no patients suf-
fered from GI toxicities. The acute toxicity was assessed
during and at the end of postoperative RT. During treat-
ment 7 patients (10.1%) experienced grade 2 GU and 4
patients (5.8%) grade 2 GI toxicity. In detail the acute
GU toxicity was described as grade 2 dysuria in 3
patients and a grade 2 increase of urinary frequency in 4
patients. In all 3 cases of dysuria a complete remission
was observed at the late toxicity follow-up, whereas one
of these patients developed a late grade 2 change of
urinary frequency. In addition, in the 4 reported cases of
acute grade 2 variation of urinary frequency, symptoms
alleviated to grade 1 urinary frequency level in the late
follow-up. Furthermore, the 4 patients that suffered
from grade 2 acute GI toxicity all had a transient grade
2 diarrhea with a reported remission in the late toxicity
follow-up. No acute grade 3 or higher GU and GI
toxicity was detected. Table 2 provides a detailed
overview of acute GI and GU toxicity.Highest grade
of GU symptoms
0 44 (63.8%) 34 (49.3%)
1 18 (26.1%) 32 (46.6%)
2 7 (10.1%) 2 (2.9%)
3 0 (0.0%) 0 (0.0%)










0 67 (97.1%) 68 (98.6%)
1 2 (2.9%) 1 (1.4%)
Diarrhea 0 45 (65.2%) 67 (97.1%)Late toxicity
Only 2 patients (2.9%) suffered from grade 2 late GU tox-
icity, whereas no late grade 2 GI or any other grade 3 or
higher toxicity was documented. One patient with former
acute grade 2 dysuria experienced a late grade 2 urinary
frequency variation and one patient who reported grade 1
baseline and acute incontinence developed a late grade 2
incontinence. See Table 2 for detailed information of late
GU and GI toxicity.1 20 (29.0%) 2 (2.9%)
2 4 (5.8%) 0 (0.0%)
Rectal pain 0 65 (94.2%) 69 (100%)
1 4 (5.8%) 0 (0.0%)
Highest grade
of GI symptoms
0 45 (65.2%) 66 (95.7%)
1 20 (29.0%) 3 (4.3%)
2 4 (5.8%) 0 (0.0%)
3 0 (0.0%) 0 (0.0%)
Abbreviations: GU genitourinary, GI gastrointestinal, CTCAE Common
Terminology Criteria of Adverse Events, RT radiation therapy
atoxicity events were defined as symptoms increasing in grade over the
respective baseline symptoms
bone patient with no End of Follow up GU toxicity due to bladder resection in
bladder cancerIPSS, QoL and ICIQ
The evaluation of the IPSS of 69 patients showed a base-
line IPSS sum with a mean of 7.7 (standard deviation
(sd) of 6.2) and IPSS sum of 7.5 (sd 5.6) at the last late
follow up after RT. No statistical significant difference of
IPSS was detected (p = 1.0). The IPSS measures were
depicted in Table 3. The comparison of baseline IPSS
sum or sum group and last late IPSS sum or sum group
values showed a considerable worsening (≥5 of IPSS) in
10 patients and a considerable improvement (≥5 of IPSS)
in 7 patients [22, 23]. The subgroup of patients with a
(≥5 of IPSS) aggravation showed in 8 cases a change
from the mild to moderate IPSS symptoms group (mild
0–7, moderate 8–19, severe 20–35) and in 2 cases from
the moderate to severe group. The patients who re-
ported a significant IPSS improvement switched in four
cases from moderate to mild IPSS sum group, in two
cases from severe to moderate group and in one case
from the severe to the mild sum group. Figure 1 depicts
all IPSS group changes, including changes of IPSS sum
groups without a sum difference of ≥5 IPSS.The patient reported QoL (IPSS-QoL score) was
assessed before start of RT and at the end of follow-
up. 64 patients reported their QoL using the IPSS-
QoL score which is scaled from 0 = delighted to 6 = ter-
rible. For analysis the score was dichotomized as 0–2
(satisfied) and 3–6 (dissatisfied) [22]. Overall 18
Table 3 Baseline and late IPSS, ICIQ and IPSS-QoL assessment
Variable Baseline Last Follow-up
n (%) mean (sd) n (%) mean (sd) p-value#
IPSS:
IPSS value 69 (100%) 7.7 (6.2) 68 (98.6%) 7.5 (5.6) 1.000
missing 0 1 (1.4%)
IPSS grouped:
Mild (0–7) 40 (58.0%) 38 (55.1%)
Moderate (8–19) 25 (36.2%) 28 (40.6%)
Severe (20–35) 4 (5.8%) 2 (2.9%)
ICIQ:
ICIQ value: 64 (92.8%) 5.8 (4.7) 68 (98.6%) 5.6 (4.2) 0.874
missing 5 (7.2%) 1 (1.4%)
ICIQ grouped:
No incontinence (0) 15 (21.7%) 15 (21.7%)
Mild incontinence (1–5) 18 (26.1%) 20 (29.0%)
Moderate incontinence (6–10) 21 (30.4%) 24 (34.8%)
Severe incontinence (≥11) 10 (14.5%) 9 (13.0%)
IPSS-QoL score grouped:a
Satisfied (0–2) 47 (68.1%) 49 (71.0%)
dissatisfied (3–6) 18 (26.1%) 19 (27.6%)
missing 4 (5.8%) 1 (1.4%)
Abbrevations: sd standard deviation, IPSS International Prostate Symptom Score, ICIQ International Consultation on Incontinence questionnaire, QoL quality of life
#by paired t-Test
aIPSS-QoL-Score: 0 = delighted to 6 = terrible
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were dissatisfied after RT (Table 3). Further patient re-
ported QoL measures were detected using the EORTC
QQL-PR25 questionnaire. Patients reported no signifi-
cant changes in urinary symptoms (p = 0.349), bowel
symptoms (p = 0.888), sexual activity (p = 0.794) and
sexual functioning (p = 1.000) at last follow compared
to the baseline assessment. See Table 4 for details.Fig. 1 Late IPSS sum groups stratified by baseline IPSS sum groups. AbbrevThe ICIQ data of 64 patients showed an ICIQ sum with
a mean of 5.8 (sd 4.7) before beginning and a mean of 5.6
(sd 4.2) at the last follow up. The distribution to the differ-
ent ICIQ groups (0 = no incontinence, 1–5 = mild incon-
tinence, 6–10 = moderate incontinence, ≥11 = severe
incontinence) is depicted in Table 3. The comparison of
ICIQ sum before and after RT showed no statistical
significant worsening of ICIQ score after RT (p = 0.874).iations: IPSS = International Prostate Symptom Score
Table 4 Baseline and late patient reported quality of life scores (QLQ-PR25)
QLQ-PR25 Baseline Last Follow-up
Number of respondents mean (sd) Number of respondents mean (sd) p-value#
Symptom Scales:a
Urinary symptoms (PRURI) 41 26.9 (17.0) 68 25.1 (17.1) 0.349






Sexual activity (PRSAC) 34 57.4 (28.8) 51 57.2 (31.0) 0.794
Sexual functioning (PRSFU) 15 48.9 (15.1) 23 48.9 (14.7) 1.000
Abbreviations: QLQ-PR25 EORTC quality of life prostate cancer module PR25, sd standard deviation
#by paired t-Test
aRange 0–100, with a positive score indicating a worsening
bRange 0–100, with a positive score indicating an improvement
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Within a follow-up period of median 20 month 7 pa-
tients (10.1%) experienced BF. The time from RT to BF
ranged from 4 to 40 month with a median of 16 month.
To differ between local recurrence and distant failure
further diagnostic was applied following the diagnosis of
BF. In one patient the localization of recurrence was
shown as bone metastasis in a bone scintigraphy. Further,
in three patients a 68Ga PSMA-PET/CT scan detected a
recurrence in the iliac lymph node region and the fifth pa-
tient suffered from a recurrence in the iliac and paraaortic
lymph node region, also verified by a 68Ga PSMA-PET/
CT scan. The other two patients with BF refused the
further diagnostic procedures.
Thus, considering these findings, in 5 of the 7 patients
with biochemical failure no local prostate bed recurrence
was detected. In the other two cases there is no information
available on the pattern of recurrence.Table 5 Univariate and multiple Cox regression analysis of factors a
Factor
Univariate Cox regression:
Age: ≤65 versus >65 (years)
ECOG performance status: 0 versus >1
Lymphnode involvement: N0 versus N1
Gleason score: ≤7 versus ≥8
Surgical margins: R0 versus R1
Androgen deprivation therapy: no or yes
Pelvic nodal RT: no or yes
Presurgery PSA: ≤10 versus >10 (ng/ml)
PSA Persistance after surgery: <0.5 versus ≥0.5 (ng/ml)
PSA at start of RT <0.5 versus ≥0.5 (ng/ml)
Multivariate Cox regression:
Presurgery PSA: ≤10 versus >10 (ng/ml)
PSA Persistance after surgery: <0.5 versus ≥0.5 (ng/ml)
Abbreviations: RR relative risk, CI 95% confidence intervals, RT radiation therapy, p p
specific antigenIn our cohort a 2-year bPFS of 91% was observed. Add-
itional analysis showed no significant factors for the develop-
ment of a biochemical failure in multivariate cox regression.
In univariate cox regression a persistent PSA ≥ 0.5 mg/ml
after RP was associated with decreased bPFS (p = 0.046) and
a presurgery PSA of >10 ng/ml showed a trend towards
worsening of bPFS (p = 0.082, Table 5).
Discussion
The results of this retrospective analysis in prostate cancer
patients who received risk adapted dose-intensified RT
after RP showed low rates of relevant acute and late GU
and GI toxicity, no significant worsening of symptoms
burden (IPSS, ICIQ), no significant change in QoL and
comes along with promising biochemical control rates.
The reported minor rates of acute GU and GI toxicities,
appeared during and at the end of RT, with 10.1% grade 2














-value, ECOG Eastern Cooperative Oncology Group, PSA prostate
Beck et al. Radiation Oncology  (2017) 12:125 Page 7 of 10grade 3 or higher acute toxicity were favorably comparable
with and even were slightly below toxicity rates of already
published postoperative RT trials. In addition, the low
number of observed late toxicity with 2.9% of grade 2 GU
toxicity and no other late ≥ grade 2 toxicity demonstrated
a good tolerability of the administered dose-intensified
postoperative RT. Several previous published retrospective
studies showed remarkable toxicity rates associated with
dose escalated RT. Administering a SRT (2D and 3D con-
formal techniques) with a median dose of 72 Gy Cozzarini
et al. reported ≥ grade 2 late GU toxicity in 23.7 and 10%
grade 3 late GU toxicity [CTCAEv3.0; median follow-up
99 month] [24]. Furthermore, Ost et al. observed 22% late
≥ grade 2 GU toxicity and 3% late grade 3 GU toxicity in
patients who received a SRT in intensity-modulated radi-
ation therapy (IMRT) technique with a median dose of
76 Gy [CTCAEv3.0; median follow-up 5 years] [13]. A
comparison of three-dimensional (3D) versus IMRT SRT
with doses between <66 Gy up to ≥70Gy, published by
Goenka et al., showed a rate of ≥ grade 2 late GI toxicity
in 1.9% of patients treated with IMRT versus 10.2% when
treated with 3D conformal techniques. Aside from the
8.3% reduction of late GI toxicity using IMRT no signifi-
cant difference in ≥ grade 2 late GU toxicity between both
techniques was seen with an overall rate of 16.3% ≥ grade
2 late GU toxicity [CTCAEv3.0; median follow-up
60 month]. In the cohort treated with IMRT the IPSS was
assessed and the average IPSS of patients was 5.24 (range
0–19) before SRT and the average maximum after SRT
was 7 (range 0–30) [18, 25]. Whereas, the above men-
tioned studies all applied dose-intensified RT to the whole
prostate bed, a trial published by Zilli et al. described the
SRT (3D conformal technique and a minority treated with
IMRT) with a boost to the suspected relapse regions visu-
alized by aid of endorectal magnetic resonance imaging
(eMRI) with 74 Gy and a prostate bed dose of 64 Gy.
Acute Grade 2 GU and GI toxicities were reported in
12.3 and 19.3%. Furthermore, 1.8% of patients experi-
enced acute grade 4 urinary obstruction and 6.4% of
patients suffered from late grade 2 GU toxicity and
grade 2 GI toxicity. Late Grade 3 GU toxicity was also
observed in 6.4% and late grade 3 GI toxicity was re-
ported in 1.8% [Radiation Therapy Oncology Group
(RTOG) scoring and CTCAEv3.0] [26]. Our results
show a lower rate of acute and late GU and GI toxic-
ities, using a dose-intensified risk adapted boost of
70.3 Gy in a prostate bed partial volume and a dose of
66.6 Gy for the whole prostate bed. The smaller vol-
ume with a moderate intensified dose is assumed to
cause the better tolerability. Moreover in our study all
patients were treated with helical tomotherapy treat-
ment technique, ensuring sufficient sparring of risk
organs. However, concerning the late toxicity results it
must be noted that the median follow-up of 20 monthdepicts a limitation of our study, because particularly
late GU toxicities are even reported to occur up to
10 years after RT.
The to date only prospective dose intensified SRT trial
(SAKK 09/10) recently reported comparable, but also
slightly higher acute toxicity rates, using a similar inten-
sified dose for radiation of the whole prostate bed. This
trial observed 13% acute grade 2 GU toxicity and 0.6%
grade 3 GU toxicity in the 64 Gy arm compared to
16.6% acute grade 2 toxicity and 1.7% grade 3 GU tox-
icity when 70 Gy were applied. Acute grade 2 GI toxicity
occurred in 16%, grade 3 GI toxicity in 0.6% treated with
64 Gy compared to 15.4 and 2.3% acute grade 2 and 3
GI toxicity after 70 Gy, respectively [CTCAEv4.0]. No
significant differences in acute toxicities between both
arms were detected. Interestingly, the trial was also
stratified for radiation technique (3D vs. IMRT/rota-
tional RT) and in contrast to former mentioned studies
no significant influence on acute toxicity was monitored.
Furthermore, a significantly increased patient reported
genitourinary symptom burden was observed in the
70 Gy arm [20].
In this context, it was assumed that high dose RT to ur-
ethra and vesico-urethral anastomosis as applied in dose
escalated whole prostate bed RT schemes results in similar
GU toxicity regardless of RT technique [27]. From that
point of view the partial prostate bed SIB-volume could be
supposed to explain the low GU toxicity rates in our study.
To discuss the toxicities it is also worth mentioning,
that physician-assessed toxicity scoring systems like
CTCAEv.4.0 may underestimate the patients symptoms
burden and may neglect important problems of the
patient [20, 28].
Therefore it is important to consider patient reported
toxicity scoring systems like IPSS or ICIQ as well as pa-
tient reported QoL. In our study patients reported their
urinary symptoms (IPSS questionnaire) and incontinence
symptoms (ICIQ questionnaire) before the beginning of
RT and at the end of follow-up. Comparing these
surveys, both scores showed no statistical significant dif-
ference, neither worsening nor improvement (Table 3).
Consequently, the patients’ evaluation of the treatment
also showed a good long term tolerability of the applied
postoperative radiation scheme. Comparable IPSS values
where registered by Geonka et al. in dose intensified
SRT using IMRT [18]. Another important evaluation of
the treatment is the patients’ perception of their QoL.
Patients assessment of their QoL before RT and at the
end of follow-up showed no statistical significant differ-
ence. Thus, no long term variation of QoL could be
detected (Tables 3 and 4).
Within a median follow-up of 20 month 7 patients
(10.1%) developed a BF and the calculated 2-year bPFS
was 91%. With the aid of further diagnostics (ga-68
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local recurrence in the prostate bed was excluded,
confirming a promising local control. For the remaining
two patients the localization of recurrence is unknown.
These data of biochemical control represent a first hint
that our applied postoperative radiation scheme seems
to be a promising treatment option, whereas the short
follow up period is a limitation. Further analysis of the
data showed a persistent PSA ≥ 0.5 mg/ml after RP was
significantly associated with decreased bPFS in the uni-
variate analysis and a presurgery PSA >10 ng/ml showed
also a trend for a decrease in bPFS: Whereas, further
established risk factors showed no trend or significant
influence in our cohort (Table 5). The limited follow-up
and the size of the cohort are assumed to be reasons for
these results.
However, it should be taken into account that approxi-
mately one-third of patients in our study received an
additional ADT. Consequently it may have influenced
the biochemical outcome as well as toxicity and QoL.
For example, data of two randomized studies combining
SRT and ADT were recently published. The GETUG-AFU
16 trial observed a significant improvement in 5-year
progression-free survival for combination of 66 Gy SRT
with additional 6 month goserelin versus 66 Gy SRT alone
(80% versus 62%; p < 0.0001). No significant difference in
overall survival (OS) was reported. In the combined treat-
ment arm more acute < grade 3 toxicities were registered
than in SRT alone [29]. RTOG 9601 trial applied either
SRT with 64.8 Gy plus 24-month bicalutamide or SRT
with 64.8 Gy alone. The authors reported a significant OS
benefit for combined treatment after 12 years with 76.3%
versus 71.3% (HR 0.77; 95% CI, 0.59–0.99; p = 0.04). Sub-
group analysis showed particularly an OS benefit for pa-
tients with PSA levels of 0.7–1.5 ng/ml (HR 0.61; 95% CI,
0.39–0.95; p = 0.03) and PSA > 1.5 ng/ml (HR 0.45; 95%
CI, 0.25–0.81; p = 0.007). Notable differences in toxicity
between both arms were a rate of 70% gynecomastia in
the bicalutamide group versus 11% in the SRT only group
[30]. Nevertheless, it is important to bear in mind that
ADT is associated with multiple short and long term side
effects like bone loss, hot flashes, metabolic changes and
gynecomastia [31]. Thus, considering these results and the
reported toxicities it has not been finally clarified whether
in postoperative treatment schemes like ours, all or nei-
ther patients should receive ADT, what kind of ADT
should be applied and for which duration. Surely it
remains an individual decision taking into account the
patients risk factors.
As an additional limitation of our study, it must be
kept in mind that the risk adapted SIB volume was, as
described in the methods section, mainly defined consid-
ering histological findings and only in some cases
additional diagnostic information (68Ga PSMA-PET/CT,MRI, choline-PET/CT) was applied. Consequently it is
possible that in some cases the boost volume doesn’t
reflect the whole high risk relapse region of the prostate
bed and the postulated additional effect of the dose-
intensified radiation would be missed. This limitation
could be optimized by using additional information like
68Ga PSMA-PET/CT or MRI for the delineation pro-
cedure [32–35]. However, all patients received a dose of
66.6 Gy to the whole prostate bed and therefore a suffi-
cient dose for potential control of the relapse region.
Taking into account the reported limitations (e.g. the
short follow up) our presented treatment scheme with a
risk adapted dose-intensified SIB using the tomotherapy
treatment system and the reported low rate of toxicity,
no variation of QoL and a favorable biochemical recur-
rence free outcome depicts an option for a modern well
tolerated treatment in case of BF after RP or in high risk
postoperative situations (T3, R1). However these retro-
spective findings should be verified in prospective trials.
A future treatment scheme could be improved by using
68Ga PSMA-PET/CT and MRI additional to histological
findings for definition of risk adapted SIB volumes in all
treated patients. Otherwise, an early initiation of treat-
ment (PSA <0.5 ng/ml) in the SRT setting should be
considered in a future trial.Conclusions
With a low rate of relevant acute and late GU and GI
toxicity, no significant worsening of symptoms burden
(IPSS, ICIQ) and no significant change in QoL the post-
operative prostate cancer RT with a dose-intensified risk
adapted SIB applied in our study seems to be a favorable
and well tolerable therapy that comes along with promising
biochemical control rates. However as main limitations the
short follow-up, the moderate size of the cohort and the
retrospective design should be considered and thus our
approach should be verified in a future prospective trial.
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